



Biofilm capability of *staphylococcus* strains isolated from food and the anti-biofilm activity of a chemically synthesized pyrrolomycin

Cusimano M.G¹ §. Raimondi M.V.² § Schillaci D². Nocera P¹. Cascioferro S². Di Marco Lo Presti V. Vitale M^{1*}

¹Istituto Zooprofilattico Sperimentale della Sicilia “A. Mirri”, Via Gino Marinuzzi 3, 90129 Palermo (Italy);

²Dept. of Biological, Chemical and Pharmaceutical Science and Technology (STEBICEF). University of Palermo, -Palermo Italy

§ The two authors contributed equally to the work

*Corresponding Author: Author Maria Vitale , ¹Istituto Zooprofilattico Sperimentale della Sicilia “A. Mirri”, Via Gino Marinuzzi 3, 90129 Palermo (Italy);; Email: marvitus@yahoo.com

Article history: Received: 7 July 2018; Revised: 29 July 2018; Accepted: 2 August 2018

Abstract:

This electronic document is a “live” template. The various components of your paper [title, text, tables, figures and references] are already defined on the style sheet, as illustrated by the portions given in this document.

Keywords: Biofilm; *Staphylococcus* spp; *ica*; *bap*; *Sas C*; food isolates; anti-biofilm; pyrrolomycin; antibiofilm

Introduction

Food transmitted diseases are a big issues for public health worldwide and food-borne outbreaks from several sources are continuously reported caused by different infectious agents, as reviewed in Vitale and Schillaci (2016). Bacterial infection and contamination can be more complex and difficult to treat when pathogenic bacteria are organized in structural community named biofilms. Biofilm bacteria are more resistant to drugs and other treatments and their important role for infectious diseases in animals, has been explored in the last decades (Clutterbuck *et al.* 2007).

However biofilms are also a big concern for food safety for the contamination of surfaces and equipment in food processing industries (Srey, *et al.* 2013). *Staphylococcus aureus* is a relevant pathogen for mastitis in dairy farms and *S. aureus* biofilms are considered important in recurrent mastitis (Melchior *et al.*, 2006).

The intercellular adhesion (*ica*) locus (Cramton *et al.*, 1999), *bap* gene (Cucarella *et al.*, 2004) and *sas C* gene (Schroeder *et al.*, 2009) are involved in the organization of staphylococcal biofilm. The infected animals can contaminate milk, dairy products, meat with a consequent major risk for food-borne transmission to humans. The discovery of new drugs against sessile bacteria is considered a good strategy to control the infection and the diffusion of food transmitted pathogens (Simões *et al.*, 2010). With the aim of discovering new antibacterial drugs active against planktonic bacteria and /or biofilms, we have focused on the pyrrolomycins (Schillaci *et al.*, 2010).

The evaluation of biofilm formation in food isolates of *S. aureus*, in relation to the presence of *ica*, *bap* and *sas C* was performed together with the assays for the antimicrobial activity of a new


chemically synthesized nitro-derivative pyrrolomycin, the (3,5-dichloro-2-hydroxyphenyl)(4-nitro-1*H*-pyrrol-2-yl)methanone (**IV**).

Materials and Methods

Synthesis of compound IV

Synthesis of (3,5-dichloro-2-hydroxyphenyl)(4-nitro-1*H*-pyrrol-2-yl)methanone (**IV**). The compound was synthesized and characterised as already described (Raimondi *et al.*, 2006).

Figure 1: Chemical structure of (3,5-dichloro-2-hydroxyphenyl)(4-nitro-1*H*-pyrrol-2-yl)methanone **IV**



Bacterial strains

Two reference strains: *S. aureus* ATCC 25923, *S. epidermidis* RP62A, and a group of 20 food strains of *S. aureus* were analysed. The isolates were subjected to Gram staining and biochemical analysis such as catalase and Voges-Proskauer (VP) test (BioMérieux), oxidase test (Oxoid), glucose and mannitol acidification in red phenol broth (Difco). Further identification was performed using the API Staph system (BioMérieux, Marcy l'Etoile, 20500, France).

MICs determination.

Minimum inhibitory concentrations (MICs) against planktonic strains were determined as previously described in Schillaci *et al.* (2010).

Molecular characterization

DNA was extracted using QIAamp DNA mini kit spin columns according to the manufacturer's instructions (Qiagen SpA, Milan, Italy). *Staphylococcus* spp. isolates were investigated by PCR for the presence of the intercellular adhesion (*ica*) locus, biofilm-associated protein (*bap*) as described in Cucarella *et al.* (2004) and Sas (Srinivasan *et al.* 2006).

Biofilm capability evaluation

All the staphylococcal strains were tested for their ability to form biofilms by safranin staining method (Schillaci *et al.*, 2010). The same method was also used to evaluate a preventive activity on the three strongest strains by directly adding to the diluted suspension, sub-MIC concentrations of pyrrolomycin **IV**.

Biofilm susceptibility testing, methylthiazotetrazolium (MTT) method were performed as described in Schillaci *et al.* (2010)

All biofilm assays were performed in triplicate.

Results

The results on genes showed that *bap* was present in 1/20, *ica* was detected in 16/20 strains and *sasC* in 8/20 but biofilm capability was not related to the presence of genes. (Table 1)

Table 1: Biofilm capability (Optical Density, O.D.) and genes

| <i>Staphylococcus</i> strains | D.O | <i>ica</i> | <i>bap</i> | <i>sas C</i> |
|-------------------------------|--------------|------------|------------|--------------|
| <i>S.epidermidis</i> RP 62A | 3.010 | + | - | - |
| <i>S.aureus</i> ATCC 25923 | 1.956 | + | - | + |
| <i>S.aureus</i> 708 | 1.896 | + | - | + |
| <i>S.aureus</i> 637 | 1.668 | - | - | - |
| <i>S.aureus</i> 1553 | 1.337 | + | - | + |
| <i>S.aureus</i> 353 | 1.104 | + | - | - |
| <i>S. aureus</i> 357 | 1.044 | + | - | + |
| <i>S. aureus</i> 723 | 1.016 | + | - | - |
| <i>S.aureus</i> 100 | 0.989 | + | - | - |
| <i>S.aureus</i> 722 | 0.959 | + | - | + |
| <i>S.aureus</i> 712 | 0.932 | + | - | + |
| <i>S. aureus</i> 635 | 0.855 | - | - | - |
| <i>S.aureus</i> 714 | 0.851 | + | - | - |
| <i>S.aureus</i> 242 | 0.786 | + | - | - |
| <i>S.aureus</i> 713* | 0.737 | + | + | + |
| <i>S.aureus</i> 725 | 0.713 | + | - | - |
| <i>S.aureus</i> 191 | 0.648 | + | - | - |
| <i>S.aureus</i> 1559 | 0.641 | - | - | - |
| <i>S.aureus</i> 165 | 0.585 | + | - | - |
| <i>S.aureus</i> 636 | 0.541 | - | - | - |
| <i>S.aureus</i> 711 | 0.528 | + | - | + |
| <i>S.aureus</i> 1704 | 0.391 | + | - | + |

Biofilm formation strength, was high in the two references strains followed by *S. aureus* isolate N708 (*ica*⁺, *bap*⁻ and *sas C*⁺); similar OD values were obtained with the *S aureus* isolate (N 635.) in which all three loci are absent. The N 713 strain, presenting all three genetic loci showed a 50% biofilm capability compared to N 708. The analysis of antibacterial activity of the compound IV showed that it was effective against all planktonic forms of the tested strains with MICs values ranging from 0.4 to 0.2 µg/mL. The strongest biofilm producers N708, together with the reference strains *S.aureus* ATCC 25923, and *S. epidermidis* RP62A, were used to evaluate the anti-biofilm properties of pyrrolomycin IV on 24 hours established biofilms and before biofilm formation. The anti-biofilm activity against 24 hours pre-formed biofilm was observed at concentrations of 1.6 or 0.8 µg/mL, which were higher compared to the MIC values obtained on planktonic forms (Tab.2).

Table 2: Anti-microbial activity of pyrrolomycin IV against the stronger biofilm producer strains

| Strains | MIC (µg/mL) (no growth in planctonic) | MIC (µg/mL) in preformed biofilm | | | |
|-----------------------------|---|-------------------------------------|------|------|-----|
| | | 1.6 | 0.8 | 0.4 | 0.2 |
| <i>S. epidermidis</i> RP62A | 0.4 | 92.4 | 89.5 | 33.6 | NS |
| <i>S. aureus</i> ATCC 25923 | 0.2 | 54 | 41 | 30.6 | NS |
| <i>S. aureus</i> 353 | 0.2 | 89 | 66 | 20 | NS |
| <i>S.aureus</i> 708 | 0.4 | 80.6 | 62.5 | 27 | NS |
| <i>S.aureus</i> 723 | 0.2 | 88 | 79 | 19 | NS |

Values are the average of at least three independent determinations.

Variation coefficient was less than 15%. NS = not significant because below the 15% of inhibition.

The anti-planktonic activity showed MIC values between 0.2 and 0.4 for all isolates.

A higher MIC values (0.8-1.6) were necessary to inhibit at least 62% in the preformed biofilm of the field isolates.

An ability of the compound to prevent biofilm on two reference staphylococcal strains and *S.aureus* strain N 708, was shown at concentrations of 0.18, 0.09 and 0.045 µg/mL, lower than the MIC values established in planktonic forms. Indeed, almost 50% of biofilm was inhibited at concentration of 0.09 µg/mL (Table 3).

Table 3: Inhibition of biofilm formation at sub-MIC concentrations(µg/mL)

The activity is expressed as percentage of inhibition.

| Strains | 0.18 | 0.09 | 0.045 |
|-----------------------------|------|------|-------|
| <i>S. epidermidis</i> RP62A | 46.4 | 43.1 | 34.7 |
| <i>S. aureus</i> ATCC 25923 | 56.5 | 44.5 | 29.1 |
| <i>S. aureus</i> 708 | 55 | 52 | 42.5 |

An average of 52% and 46% inhibitor percentage was present at sub MIC concentration of 0.18 and 0.09 µg/mL respectively. These results look very promising for the prevention of Biofilm formation, considering the very low level of the active concentration of compound IV.

Discussion

The results showed that the capability *Staphylococcus* spp. strains in biofilm formation is not related to the presence or absence of the genetic loci analysed in this study. This might be due to the fact that *in vitro* biofilm organization often depends on several factors such as the composition of the culture media (Ferreira et al. 2012). In contrast to human isolates, the lack of a role for the *ica* operon on the formation of biofilm by *S.aureus* isolates from bovine mastitis, has already been described (O'Gara 2007). The existence of alternative mechanisms to induce biofilm development implies that each *S. aureus* isolate might develop a particular type of biofilm matrix to better suit the environmental conditions (Schroeder et al., 2009).

Bacterial infections in livestock animals represent a big concern for food safety since the pathogenic bacteria can contaminate food products and transmit infection and disease to humans. Animal with clinical or subclinical mastitis caused by *S.aureus* can contaminate the milk with strains that often harbour several virulent factors like enterotoxins and toxic shock syndrome genes (Srinivasan et al. 2006). More than 280 episodes of food poisoning episodes due to staphylococcal enterotoxins have been reported each year in Europe (EFSA report, 2010). Staphylococcal enterotoxins poisoning cases and the circulation of virulent *S. aureus* strains in milk and food samples have been reported already in Sicily, Italy where mastitis problems in cattle and sheep are frequently reported (Vitale et al 2015, 2018)

Conclusion

The new synthetic pyrrolomycin IV showed good antimicrobial property against planktonic form of *S. aureus* and in preventing staphylococcal biofilm. A more efficacious control of bacterial biofilm can result in a lower number of antimicrobial treatments, a reduction in the spread of antibiotic resistance and a control of pathogenic bacteria in livestock farms. The community and sessile forms of pathogenic bacteria are in fact involved in the recurrence of infection in animals but also in persistent contamination of food production premises.

Acknowledgement

We thank Prof. Salvatore Petruso for his support in the scientific project on pyrrolomycins. Drs. Maria

La Giglia and Nicola Sciurba for scientific support.

Funding Information

Fondi di Ateneo 2006, 2007 University of Palermo (Italy) to D.S. and R/C 2015 and 2016 by Italian Ministry of Health (Italy) to M.V.

Author's Contributions

MGC and MVR contributed to compound synthesis and biofilm assays. P.N performed genetic analysis. MV, D.S and VDLP supervised and planned the work, MV and DS contributed to manuscript writing, all authors approved the manuscript.

Ethics

The work did not involve any experiments on animals. All authors declare that no conflict of interest is present. The work is an original paper and is not under consideration in other journals.

References

- Clutterbuck, A.L., Woods EJ. Knottenbelt DC. Clegg PD. Cochrane CA. Percival SL 2007.** Biofilms and their relevance to veterinary medicine. Veterinary Microbiology, 121: 1-17. DOI:10.1016/j.vetmic.2007.05.029.
- Cramton, SE. Gerke C. Schnell NF. Nichols WW. Gotz F. 1999.** The intercellular adhesion (*ica*) locus is present in *Staphylococcus aureus* and is required for biofilm formation. Infection and. Immunity, 67: 5427–5433. PMCID: PMC96900.
- Cucarella C. Tormo MA. Ubeda C. Trotonda MP. Monzon M. Peris C. Amorena B. Lasa I. Penades JR. 2004.** Role of biofilm-associated protein Bap in the pathogenesis of bovine *Staphylococcus aureus*. Infection and. Immunity, 72: 2177–2185. DOI: 10.1128/IAI.72.4.2177-2185.2004.
- European Food Safety Authority.2010.** The community summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in the European Union in 2008. EFSA Journal, 8: 1496-1906. DOI: 10.2903/j.efsa.2010.1496.
- Ferreira,FA. Souza RR. Bonelli RR. Américo MA. Fracalanza SE. Figueiredo AM. 2012.** Comparison of in vitro and in vivo systems to study ica-independent *Staphylococcus aureus* biofilms. Journal of Microbiological Methods. 88: 393-398. DOI: 10.1016/j.mimet.2012.01.007.
- Melchior MB. Vaarkamp H. Fink-Gremmels J 2006.** Biofilms: a role in recurrent mastitis infections? Veterinary Journal. 171: 398-407. DOI: 10.1016/j.tvjl.2005.01.006.
- O'Gara JP 2007.** *ica* and beyond: biofilm mechanisms and regulation in *Staphylococcus epidermidis* and *Staphylococcus aureus*. FEMS Microbiology Letters 270: 179-188. DOI: 10.1111/j.1574-6968.2007.00688.x.
- Raimondi MV. Cascioferro S. Schillaci D. Petruso S 2006.** Synthesis and antimicrobial activity of new-bromine-rich pyrrole derivatives related to monodeoxypyoluteorin. European Journal of Medicinal Chemistry. 41: 14394-1445. doi.org/10.1016/j.ejmech.2006.07.009.
- Schillaci D. Petruso S. Raimondi MV. Cusimano MG. Cascioferro S. Scalisi M. La Giglia A.M. Vitale 2010.** Pyrrolomycins as potential anti-staphylococcal biofilm agents. Biofouling. 26: 433-438. doi.org/10.1080/08927011003718673.
- Schroeder K. Jularic M. Horsburgh SM. Hirschhausen N. Neumann C. Bertling A. Schulte A. Foster S. Kehrel BE. Peters G. Heilmann C 2009.** Molecular Characterization of a Novel *Staphylococcus aureus* Surface Protein (Sas C) Involved in Cell Aggregation and Biofilm Accumulation. PLoS ONE. 4(10): e7567. doi:10.1371/journal.pone.0007567.

- Simo˜es ML. Simo˜es C. Vieira MJ 2010.** A review of current and emergent biofilm control strategies. LWT - Food Science and Technology. 43: 573–583. doi:10.1016/j.lwt.2009.12.008.
- Srey S. Jahid IK. Ha SD 2013.** Biofilm formation in food industries: A food safety concern. Food Control. 31: 572–585. doi.org/10.1016/j.foodcont.2012.12.001.
- Srinivasan V. Sawant AA. Gillespie BE. Headrick SJ. Ceasaris L. Oliver SP 2006.** Prevalence of enterotoxin and toxic shock syndrome toxin genes in *Staphylococcus aureus* isolated from milk of cows with mastitis. Foodborne Pathogens and Disease, 3: 274-283. DOI: 10.1089/fpd.2006.3.274.
- Vitale, M., Scatassa ML. Cardamone C. Oliveri G. Piraino C. Alduina R. Napoli C 2015.** Staphylococcal Food Poisoning Case and Molecular Analysis of Toxin Genes in *Staphylococcus aureus* Strains Isolated from Food in Sicily, Italy. Foodborne Pathogens and Disease. 12(1): 21-23. doi.org/10.1089/fpd.2014.1760.
- Vitale M. Schillaci D 2016.** Food Processing and Foodborne Illness Reference Module in Food Sciences. Editors: Elsevier doi.org/10.1016/B978-0-08-100596-5.03144-9 .
- Vitale M. Gaglio S. Galluzzo P. Cascone G. Piraino C. Di Marco V. Presti Lo. Alduina R 2018.** Antibiotic resistance profiling, analysis of virulence aspects and molecular genotyping of *Staphylococcus aureus* isolated in Sicily, Italy. Foodborne Pathogens and Disease. 15(3): 177-185. doi:10.1089/fpd.2017.2338.